Tabomedex Biosciences, Inc. Company
Tabomedex focuses on the R&D of new drugs related to type 2 diabetes. They mainly study the mechanism of action of MK2 and achieve the effect of controlling blood glucose level by inhibiting MK2, namely inhibiting the effect of downstream avtivating enzymes.
Industry:
Geroscience
Headquarters:
Boston, Massachusetts, United States
Zip:
1-10
Founded Date:
2013-01-01
Employees Number:
1-10
Acquisitions Number:
3
Investors Number:
5000000
Total Funding:
$1M to $10M
Estimated Revenue:
$1M to $10M
Last Funding Date:
Series A
Last Funding Type:
alice@tabomedex.com
Register and Claim Ownership